X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Venetoclax,Rituximab
Therapeutic Area: Oncology Product Name: Venclexta
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2020
Details:
Phase 3 MURANO trial shows median progression-free survival of 53.6 months in previously treated CLL patients taking VENCLEXTA/VENCLYXTO in combination with rituximab Vs. 17.0 months in patients taking bendamustine plus rituximab after three years or more off treatment.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Venetoclax,Obinutuzumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 14, 2020
Details:
AbbVie to present data from the CLL14 trial evaluating venetoclax in combination with obinutuzumab in patients with previously-untreated CLL and Extended follow-up from subgroup-analyses of MURANO trial of venetoclax in combination with rituximab in relapsed/refractory CLL.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Venetoclax,Cytarabine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 03, 2020
Details:
AbbVie and Roche’s Venclexta has failed to significantly improve overall survival in an acute myeloid leukaemia (AML) trial that was supposed to confirm its efficacy.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Venetoclax
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2020
Details:
Study did not demonstrate statistically significant improvement in the primary endpoint of overall survival (OS) (Hazard Ratio [HR]=0.75, [95% CI 0.52 - 1.07], p=0.11)
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Bevacizumab,Carboplatin,Paclitaxel
Therapeutic Area: Oncology Product Name: HD204
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Pharmapark
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 15, 2021
Details:
The partnership arrangement includes the exclusive rights for Pharmapark to commercialize the Bevacizumab biosimilar in the Russian Federation, leveraging the company’s strong sales and marketing capabilities and experience in successfully bringing new biosimilars to market.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
